Symvivo Corporation, a clinical-stage biotechnology company advancing a proprietary bacTRL™ gene delivery platform, announced today that it has entered into a research collaboration with Merck, known as MSD outside the United States and Canada. Under the terms of the agreement, Merck receives an option to take an exclusive license to Symvivo’s bacTRL™ platform technology for use in advancing delivery of oral vaccines.  

“We are excited to be collaborating with Merck on this novel program,” said Lloyd Mackenzie, President and Chief Operating Officer at Symvivo. “This agreement builds on Symvivo’s efforts to develop the bacTRL™ platform across a range of diverse and important indications.”  

Canadian Media:

Chantal Allan
Sam Brown Inc. Healthcare Communications
T: 613-319-4384 (CAN)
T: 805-242-3080 (US)
E: chantalallan@sambrown.com


US Media:

Mike Beyer
Sam Brown Inc. Healthcare Communications
T: 312-961-2502
E: mikebeyer@sambrown.com